Armata Pharmaceuticals (ARMP) Total Non-Current Liabilities (2013 - 2020)

Armata Pharmaceuticals has reported Total Non-Current Liabilities for 8 years, with the latest figure at $20.7 million in Q4 2020.

• Quarterly Total Non-Current Liabilities rose 117.21% year-over-year to $20.7 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $20.7 million (up 117.21% YoY) and the FY2020 annual result came in at $20.7 million, up 117.21% from the prior year.
• Total Non-Current Liabilities grew to $20.7 million in Q4 2020 per ARMP's latest filing, from $9.5 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $20.7 million in Q4 2020 and troughed at $2.9 million in Q1 2018.
• A 5-year average of $6.6 million and a median of $5.7 million in 2018 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2016 and 2019: Total Non-Current Liabilities tumbled 76.66% in 2016, then jumped 284.42% in 2019.
• Over 5 years, Total Non-Current Liabilities stood at $6.0 million in 2016, then slumped by 47.97% to $3.1 million in 2017, then jumped by 84.08% to $5.7 million in 2018, then surged by 65.87% to $9.5 million in 2019, then surged by 117.21% to $20.7 million in 2020.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $20.7 million, $9.5 million, and $9.9 million for Q4 2020, Q4 2019, and Q3 2019 respectively.